Literature DB >> 426556

Effect of dextran on factor VIII (antihemophilic factor) and platelet function.

M Aberg, U Hedner, S E Bergentz.   

Abstract

Three different properties of factor VIII (antihemophilic globulin) were studied after infusion of 500 ml of six per cent Dextran 70 to healthy volunteers. This dose caused no change in the factor VIII coagulant activity while there was a significant but temporary decrease of factor VIII related antigen. The Ristocetin induced platelet aggregation analysed with native as well as with formalin-fixed platelets, also decreased significantly. The maximal decrease was found a few hours after the infusion. The decrease was seen only if Dextran was infused in vivo and not if Dextran was added to blood in vitro. The dysfunction of factor VIII caused by Dextran resembles that found in one variant of von Willebrand's disease. This finding probably explains the platelet function inhibiting properties of Dextran, and may be of significance for its antithrombotic effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 426556      PMCID: PMC1397039          DOI: 10.1097/00000658-197902000-00017

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

Review 1.  Platelet physiology and abnormalities of platelet function (second of two parts).

Authors:  H J Weiss
Journal:  N Engl J Med       Date:  1975-09-18       Impact factor: 91.245

2.  Determination of fibrinogen and fibrinogenolytic activity.

Authors:  I M NILSSON; B OLOW
Journal:  Thromb Diath Haemorrh       Date:  1962-11-15

3.  A method for measuring plasma ristocetin cofactor activity. Normal distribution and stability during storage.

Authors:  M Zuzel; I M Nilsson; M Aberg
Journal:  Thromb Res       Date:  1978-05       Impact factor: 3.944

4.  Von Wollebrand's disease with normal Factor VIII activity in a homozygote.

Authors:  L Holmberg; N Rasović; I M Nilsson
Journal:  Haemostasis       Date:  1974

5.  Effects of dextran infusion on the adhesiveness of human blood-platelets.

Authors:  P N Bennett; D P Dhall; F N McKenzie; N A Matheson
Journal:  Lancet       Date:  1966-11-05       Impact factor: 79.321

6.  Isolation and characterization of human Factor VIII (antihemophilic factor).

Authors:  M E Legaz; G Schmer; R B Counts; E W Davie
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

7.  Studies of the human factor VIII/von Willebrand's factor protein. II. Identification and characterization of the von Willebrand protein.

Authors:  H R Gralnick; B S Coller
Journal:  Blood       Date:  1975-09       Impact factor: 22.113

8.  Genetic variants of von Willebrand's disease.

Authors:  L Holmberg; I M Nilsson
Journal:  Br Med J       Date:  1972-08-05

9.  Effects of porcine plasmin on the coagulation and fibrinolytic systems in humans.

Authors:  U Hedner; L Johansson; I M Nilsson
Journal:  Blood       Date:  1978-01       Impact factor: 22.113

10.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.

Authors:  H J Weiss; L W Hoyer; F R Rickles; A Varma; J Rogers
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

View more
  14 in total

Review 1.  Colloid volume expanders. Problems, pitfalls and possibilities.

Authors:  J S Roberts; S L Bratton
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

2.  Fluid resuscitation with colloid or crystalloid solutions. Comparing different studies is difficult.

Authors:  J Watts
Journal:  BMJ       Date:  1998-07-25

3.  The use of blood components in surgical transfusion therapy.

Authors:  C F Högman; L Bagge; L Thorén
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

4.  Dextran in the prophylaxis of pulmonary embolism.

Authors:  S E Bergentz
Journal:  World J Surg       Date:  1978-01       Impact factor: 3.352

Review 5.  The use of plasma substitutes with special attention to their side effects.

Authors:  K F Messmer
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

6.  Therapeutic effect of isovolemic hemodilution with dextran 60 on the impairment of pancreatic microcirculation in acute biliary pancreatitis.

Authors:  E Klar; C Herfarth; K Messmer
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

Review 7.  Use of plasma volume expanders in myocardial revascularisation.

Authors:  J H Lacy; C B Wright
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

8.  Dextran administration avoids hemodynamic changes following paracentesis in cirrhotic patients. A safe and inexpensive option.

Authors:  R Terg; J Berreta; R Abecasis; G Romero; L Boerr
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

9.  Effect of dextran on platelet activation by polymerizing fibrin.

Authors:  C H Ts'ao; D V Krajewski
Journal:  Am J Pathol       Date:  1982-01       Impact factor: 4.307

Review 10.  Postoperative fluid management.

Authors:  Selami Ilgaz Kayilioglu; Tolga Dinc; Isa Sozen; Akin Bostanoglu; Mukerrem Cete; Faruk Coskun
Journal:  World J Crit Care Med       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.